Use of a Multitarget Fluorescence In Situ Hybridization Assay to Diagnose Bladder Cancer in Patients With Hematuria

Journal of Urology

Volumn 176, Issue 1, 2006, Pages 44-47

  Sarosdy, Michael F ^a   Kahn, Paul R ^a   Ziffer, Mark D ^a   Love, William R ^a   Barkin, Jack ^a   Abara, Emmanuel O ^a   Jansz, Ken ^a   Bridge, Julia A ^a   Johansson, Sonny L ^a   Persons, Diane L ^a   Gibson, Jane S ^a  

^a South Texas Urology and Urologic Oncology   (United States)

Author keywords

bladder; bladder neoplasms; fluorescence; hematuria; in situ hybridization

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; CYSTOSCOPY; CYTOLOGY; EVALUATION; FEMALE; FISHER EXACT TEST; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATURIA; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; URETER CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CYSTOSCOPY; CYTODIAGNOSIS; FEMALE; HEMATURIA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE;

EID: 33744825700     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(06)00576-3     Document Type: Article

References (20)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghaffor A., et al. Cancer statistics 2005. CA Cancer J Clin 55 (2005) 10
2. Tissot W.D., Diokno A.C., and Peters K.M. A referral center's experience with transitional cell carcinoma misdiagnosed as interstitial cystitis. J Urol 172 (2004) 478
3. Wallace D.M., Bryan R.T., Dunn J.A., Begum G., and Bathers S. Delay and survival in bladder cancer. BJU Int 89 (2002) 868
4. Sanchez-Ortiz R.F., Huang W.C., Mick R., Van Arsdalen K.N., Wein A.J., and Malkowicz S.B. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169 (2003) 110
5. Chang S.S., Hassan J.M., Cookson M.S., Wells N., and Smith Jr. J.A. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 170 (2003) 1085
6. Liedberg F., Anderson H., Mansson A., and Mansson W. Diagnostic delay and prognosis in invasive bladder cancer. Scand J Urol Nephrol 37 (2003) 396
7. Grossfeld G.D., Wolf J.S., Litwin M.S., Hricak H., Shuler C.L., Agerter D.C., et al. Asymptomatic microscopic hematuria in adults. summary of AUA best practice policy recommendations. Am Fam Physician 63 (2001) 1145
8. Mao L., Schoenberg M.P., Scicchitano M., Erozan Y.S., Merlo A., Schwab D., et al. Molecular detection of primary cancer by microsatellite analysis. Science 271 (1996) 659
9. Sarosdy M.F., DeVere White R.W., Soloway M.S., Sheinfeld J., Hudson M.A., Schellhammer P.F., et al. Results of a multi-center trial using BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154 (1995) 379
10. Planz B., Jochims E., Deix T., Caspers H.P., Jakse G., and Boecking A. The role of urinary cytology for detection of bladder cancer. Eur J Surg Oncol 31 (2005) 304
11. Sauter G., Moch H., Wagner U., Novotna H., Gasser T.C., Mattarelli G., et al. Y chromosome loss detected by FISH in bladder cancer. Cancer Genet Cytogenet 82 (1995) 163
12. Cajulis R.S., Haines G.K., Frias-Hidvegi D., McVary K., and Bacus J.W. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes. a comparative study. Diagn Cytopathol 13 (1997) 214
13. Meloni A.M., Peier A.M., Haddad F.S., Powell I.J., Block A.W., Huben R.P., et al. A new approach in the diagnosis and follow-up of bladder cancer. FISH analysis of urine, bladder washings, and tumors. Cancer Genet Cytogenet 71 (1993) 105
14. Halling K.C., King W., Sokolova I.A., Meyer R.G., Burkhardt H.M., Halling A.C., et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164 (2000) 1768
15. Halling K.C., King W., Sokolova I.A., Karnes R.J., Meyer R.G., Powell E.L., et al. A comparison of BTAstat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 167 (2002) 2001
16. Sarosdy M.F., Schellhammer P., Bokinsky G., Kahn P., Chao R., Yore L., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168 (2002) 1950
17. Skacel M., Fahmy M., Brainard J.A., Pettay J.D., Biscotti C.V., Liou L.S., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169 (2003) 2101
18. Messing E.M., Young T.B., Hunt V.B., Gilchrist K.W., Newton M.A., Bram L.L., et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45 (1995) 387
19. Schroeder G.L., Lorenzo-Gomez M.F., Hautmann S.H., Friedrich M.G., Ekici S., Huland H., et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 172 (2004) 1123
20. Lokeshwar V.B., and Soloway M. Current bladder tumor tests. does their projected clinical utility fulfill clinical necessity?. J Urol 165 (2001) 1067